

CUMULATIVE INDEX 1994

Volume 20

February	SYSTEMIC LUPUS ERYTHEMATOSUS, pages 1-308
May	DIAGNOSTIC ISSUES, pages 309-534
August	OSTEOPOROSIS, pages 535-810
November	INFLAMMATORY DISORDERS OF MUSCLE, pages 811-1057

Note: Page numbers of issue and article titles are in **boldface** type.

- Abdominal pain, in vasculitis, 425-426
- Abscess, muscle, magnetic resonance imaging in, 358
- Absorptiometry, in bone density measurement, dual photon, 653-655, 789
 - dual x-ray, 655-657, 660, 789
 - radiographic, 652-653
 - single photon, 653, 789
- in inflammatory myopathy, dual-energy x-ray, 837-838
- Acetylation phenotypes, drug-induced lupus and, 72
- Acid phosphatase, tartrate-resistant, as bone resorption marker, 596
- Activated partial thromboplastin time, in lupus anticoagulant detection, 455-456
- Acute lupus pneumonitis syndrome, in SLE, 165-167
- Acute phase reactants, rheumatoid arthritis prognosis and, 313-314
- Adenovirus infections, inclusion body myositis and, 962
- Adhesion molecules, in inflammatory myopathy, 891
- Adrenal gland, hemorrhage of, in antiphospholipid antibody syndrome, 449
- Agammaglobulinemia, X-linked, myositis in, 1001-1002
- Age, rheumatoid arthritis outcome and, 311
 - vs. bone mass, 535-536, 542, 693, 700
 - gender differences in, 673-676
 - in rheumatoid arthritis, 567
 - vs. calcium absorption, 693, 763
- Alanine aminotransferase, measurement of, in myositis, 851-852, 930, 934
- Alcohol consumption, myopathy in, 1025
- osteoporosis risk and, 546
- Aldolase, measurement of, in myositis, 849-850, 921, 930-931
- Alendronate, in osteoporosis, 726
 - chemical structure of, 717
 - pharmacodynamics of, 719
 - prophylactic, 727
- Alkaline phosphatase, as biochemical marker, for bone formation, 591-593
- Alopecia, in SLE, 203
- Aluminum toxicity, in dialysis, bone histomorphometry in, 622-623
- Alveolitis, in myositis, treatment of, 913
- American trypanosomiasis, myositis in, 1009-1010
- 4-Amino-1-hydroxybutylidene-1,1'-bisphosphonate. *See* Alendronate.
- Aminohydroxypropylidene bisphosphonate, in osteoporosis, in glucocorticoid therapy, 641
- 3-Amino-1-hydroxypropylidene-1,1'-bisphosphonate. *See* Pamidronate.
- Aminotransferases, measurement of, in myositis, 851-852, 930, 934
- Amiodarone, myopathy from, 1025
- Amoxicillin, in Lyme disease, 367
- Amyloid, in inclusion body myositis, 963
- Amyloidogenic protein inclusions, in inclusion body myositis, 961

- Amyloidosis, in SLE, 184
- Anabolic steroids, in osteoporosis therapy, 640
- ANAs. See *Antinuclear antibodies*.
- Anemia, aplastic, in antimalarial therapy, 256
- Anesthetics, myopathy from, 1026
- Angiitis, leukocytoclastic, treatment of, 412
- Angiography, cerebral, in neuropsychiatric lupus, 146
- in vasculitis, 428-429
- Angiotensin-converting enzyme inhibitors, in SLE, in pregnancy, 107
- Ankylosing spondylitis, HLA typing in, 372-373
- osteoporosis in, 572-573
- Antibiotics, myopathy from, 1026
- Antibodies, anticardiolipin. See *Anticardiolipin antibodies*.
- antinuclear. See *Antinuclear antibodies*; specific antibody.
- antiphospholipid. See *Antiphospholipid antibody(ies)*.
- in lupus nephritis, 229-230
- in Lyme disease, 365-366
- in myositis, 816-817
- myositis-associated, 816-817, 858, 870-871, 899-900
- significance of, 858, 870-871
- myositis-specific, 816-817, 858-870, 899-900
- in Sjögren's syndrome, 404-405
- lymphocytotoxic, in drug-induced lupus, 68
- to cardiolipins. See *Anticardiolipin antibodies*.
- to chromatin, in SLE, 23-24
- to cytoplasm, in myositis, 860, 866-867
- to DNA, in drug-induced lupus, 8
- in lupus nephritis, 229-230
- in SLE, 2-5, 8
- to DNA replication/repair complexes, in SLE, 21-23
- to EJ antigen, in myositis, 859-860, 862
- to endothelial cells, in myositis, 870
- to Fer antigen, in myositis, 816-817, 861, 866
- to fibrillar, in myositis, 870
- to histones, in drug-induced lupus, 67-68
- in SLE, 5, 7-8
- to hydralazine, in drug-induced lupus, 68
- to Jo-1 antigen, in myositis, 858-860, 864-865
- to KJ antigen, in myositis, 816-817, 860, 866
- to Ku antigen, in myositis, 816-817, 870
- in SLE, 14-21
- to La(SSB) antigen. See *La(SSB) antigen, antibodies to*.
- to Mas antigen, in myositis, 816-817, 861, 866
- to Mi-2 antigen, in myositis, 816-817, 860, 867
- to myoglobin, in myositis, 871
- to myosin, in myositis, 871
- to neurons, in SLE, 138-139, 143
- to nucleosomes, in SLE, 5, 7-8
- to OJ antigen, in myositis, 859-860, 862, 864-865
- to phospholipids. See *Antiphospholipid antibody(ies)*.
- to PL-7 antigen, in myositis, 859-860, 862, 864
- to PL-12 antigen, in myositis, 859-860, 862
- to PM-1 antigen, in myositis, 932
- to PM-Scl antigen, in myositis, 816-817, 861, 869-870
- to procainamide, in drug-induced lupus, 68
- to proliferating cell nuclear antigen, in SLE, 22-23
- to ribonuclear proteins (RNPs), in myositis, 861, 867-869
- in SLE, 29-43
- to ribosome P, in neuropsychiatric lupus, 141, 143
- to RNA polymerase transcription complexes, in scleroderma, 11-13
- in SLE, 9-14
- to Ro(SSA) antigen. See *Ro(SSA) antigen, antibodies to*.
- to signal recognition particles (SRPs), in myositis, 816-817, 860, 866
- to Sm/U₁RNP, in mixed connective tissue disease, 32-33
- in Raynaud's phenomenon, 33
- in SLE, 29-34
- racial differences in, 33-34
- to synthetase, in myositis, 816-817, 858-860, 862-866
- to transcription complexes, in scleroderma, 11-13
- in SLE, 9-14
- to U1RNP antigen, in myositis, 861, 867-869
- to U2RNP antigen, in myositis, 861, 869
- to U3RNP antigen, in myositis, 870
- Anticardiolipin antibodies, 445-446
- detection of, 457-459
- in antiphospholipid antibody syndrome, 45, 449-450
- in normal subjects, 450-451
- in pregnancy, 50, 92
- in systemic lupus erythematosus, 451, 453

- vs. lupus anticoagulant, 446-448
- Anticoagulants, in antiphospholipid antibody syndrome, 54-55
 - in lupus nephritis, 236
 - lupus. See *Lupus anticoagulant*.
- Anticonvulsants, in drug-induced lupus, 69
- Antiestrogens, in osteoporosis, 705-706
- Antifibrinolytic agents, in lupus nephritis, 236
- Antihypertensive drugs, in SLE, in pregnancy, 106-107
- Antimalarial agents, in SLE, 243-264
 - adverse reactions of, 254-258
 - clinical trials of, 249-250
 - dosage of, 253-254
 - in pregnancy, 105
 - indications for, 250-253
 - mechanisms of action of, 244-249
 - pharmacokinetics of, 244
 - pharmacology of, 244
 - pregnancy and, 254
 - selection of, 253-254
 - synergistic activity of, 252-253
- Antineuron antibodies, in SLE, 138-139, 143
- Antinuclear antibodies. See also specific antibody.
 - in drug-induced lupus, 67-68, 71
 - in eosinophilia myalgia syndrome, 984
 - in myositis, 858, 867, 870-871
 - juvenile, 932-933
 - in Sjögren's syndrome, 404
 - in SLE, in pediatric patients, 123
 - in pleural fluid, 163-164
- Antiphospholipid antibody(ies), 443-469
 - detection of, anticardiolipin antibody, 457-459
 - lupus anticoagulant, 454-457
 - drug-induced, 47
 - in drug-induced lupus, 68
 - in false-positive syphilis test, 443-444
 - in lupus nephritis, 232
 - in normal subjects, 450-451
 - in systemic lupus erythematosus, 451-454
 - infection-induced, 47
 - measurement of, 52-53
 - types of, 444-448
- Antiphospholipid antibody syndrome, 45-59, 448-449
 - anticardiolipin antibody in, 449-450
 - brain arterial occlusion in, 48, 54-55
 - catastrophic occlusion syndrome in, 49, 55-56
 - clinical syndromes in, 48-52
 - definition of, 45-47
 - experimental models for, 53
 - kidney vessel thrombosis in, 49, 55
 - laboratory tests for, 52-53
 - livedo reticularis in, 52, 55
 - lupus anticoagulant in, 449-450
 - pregnancy and, 50, 54
 - fetal loss in, 91-93
 - preterm delivery in, 94
 - treatment of, 107-108
 - recurrent, 47
 - stroke in, 48, 54-55
 - treatment of, 54-56
 - pregnancy and, 107-108
 - valvular heart disease in, 52, 55
 - variants of, 46
 - vascular occlusion in, 48-50, 54-55
 - venous occlusion in, 49-50, 55
- Antiplatelet agents, in lupus nephritis, 236
- Anti-synthetase syndrome, in myositis, 859, 862
- Aortitis, diagnosis of, 430-432
- Aplastic anemia, in antimalarial therapy, 256
- Arteritis, giant cell (temporal). See *Giant cell (temporal) arteritis*.
- Takayasu's. See *Takayasu's arteritis*.
- Arthralgia, in eosinophilia myalgia syndrome, 978
 - in myositis, treatment of, 912
- Arthritis, arthroscopy in. See under *Arthroscopy*.
 - crystal-induced, synovial fluid analysis in, 504, 510
 - enteropathic, HLA typing in, 372
 - in anti-synthetase syndrome, 859
 - in drug-induced lupus, 64
 - in myositis, treatment of, 912
 - in SLE, in pediatric patients, 123
 - inflammatory, diagnostic arthroscopy in, 326-331
 - Lyme, 364-365
 - noninflammatory, diagnostic arthroscopy in, 332-335
 - pseudo-septic, diagnostic arthroscopy in, 331-332
 - psoriatic, HLA typing in, 372
 - osteoporosis in, 573
 - rheumatoid. See *Rheumatoid arthritis*.
 - septic. See *Septic arthritis*.
 - vasculitic, 425
- Arthrocentesis, indications for, 503-505
- Arthroscopy, diagnostic, in arthritis, 321-342
 - alternatives to, 324-325
 - diagnostic subsets for, 325
 - evolution of, 321
 - hardware for, 322-323
 - indications for, 322-323
 - inflammatory, 326-331
 - lavage effect in, 322
 - noninflammatory, 332-335
 - osteo-, 335-336

Arthroscopy (Continued)

- patient selection for, 324
- research applications of, 336-337
- septic, 331-332
- vs. therapeutic arthroscopy, 322
- therapeutic, in arthritis, 322, 337
- Aseptic meningitis, in SLE, 135
- Aspartate aminotransferase, measurement of, in myositis, 851-852, 930, 934
- Aspirin, in antiphospholipid antibody syndrome, 54-55
 - in pregnancy, 108
 - in drug-induced lupus, 71
 - in SLE, in pregnancy, 104-105
 - myopathy from, 1021
- Ataxia, cerebellar, in SLE, 134
- Atherosclerosis, in SLE, 122-123
- Atrial myxoma, diagnosis of, 422
- Autoantibodies. *See* specific antibody.
- Autoimmune disease, with inclusion body myositis, 963-964
- Autonomic neuropathy, in SLE, 136
- Avascular necrosis, from glucocorticoids, 636-637
 - in SLE, in pediatric patients, 123
 - magnetic resonance imaging in, 345-346, 351
- Azathioprine, in myositis, 907, 911
 - inclusion body, 965-966, 968
 - in SLE, 269-272, 282-284
 - anti-inflammatory effects of, 271
 - immunosuppressive effects on, 269-271
 - in interstitial lung disease, 171
 - in pneumonitis, 166
 - in pregnancy, 106
 - side effects of, 283-284
- Basic multicellular unit, in bone remodeling, 612
- Beclobrate, myopathy from, 1023
- Behçet's disease, clinical features of, 417
 - diagnosis of, 415, 419-420, 422-423, 426
 - HLA typing in, 382
 - treatment of, 413
- Bell's palsy, in Lyme disease, 364
- Bezafibrate, myopathy from, 1023
- Biochemical markers, for bone remodeling, 589-607
 - applications of, 591
 - formation phase, 591-595
 - resorption phase, 595-602
- Biophysical profile, of fetus, in SLE, 102
- Biopsy, bone. *See* Bone biopsy.
 - kidney, in SLE, 223-224, 226-228
 - liver, in methotrexate therapy, 519-520
 - muscle, in inflammatory myopathy, 828

- renal, in vasculitis, 429
- respiratory tract, in vasculitis, 427
- salivary gland, in Sjögren's syndrome, 394-395

temporal artery, 433-434

- Bisphosphonates, in osteoporosis, 717-734
 - chemical structures of, 717
 - gender differences in, 683-684
 - immobilization-induced, 728
 - in glucocorticoid therapy, 641, 727-728
 - mechanism of action of, 717-719
 - pharmacodynamics of, 719
 - postmenopausal, 720-726
 - prophylactic, 726-727
 - rationale for, 720
 - side effects of, 719-720
 - vs. other agents, 728
- Blisters, in SLE, 200-202
- Blood disorders, in methotrexate therapy, 520-521
- Body mass index, vs. osteoporosis risk, 545-546
- Bone biopsy, 609-627
 - normal skeletal intermediary organization and, 610-613
 - fracture repair, 612
 - growth, 610
 - modeling, 611
 - regional acceleratory phenomena, 613
 - remodeling, 611-612
- transilial, 613-625
 - complications of, 614
 - fluorochrome labeling in, 614-615
 - histomorphometry results in, 616-624
 - in osteomalacia, 619-622
 - in osteoporosis, 619, 632, 682-683
 - in renal osteodystrophy, 621-624
 - parameters of, 616-618
 - precautions for, 614
 - procedure for, 613-614
 - specimen preparation in, 615-616
 - trephines for, 613-614
- Bone density, calcium intake and, 692-693
- estrogen replacement effects on, 701-702
- fracture threshold and, 691
- in glucocorticoid therapy, 568, 570
- in osteoarthritis, 562-564
- measurement of, 651-669, 789
 - dual photon absorptiometry in, 653-655, 789
 - dual x-ray absorptiometry in, 655-657, 660, 789
 - gender differences in, 681-682
 - in estrogen therapy, 706
 - in glucocorticoid therapy, 638
 - quantitative computed tomography in, 658-661, 789
 - quantitative ultrasound in, 662-663

- radiographic absorptiometry in, 652-653
- single photon absorptiometry in, 653, 789
- vs. bone strength, 652
- Bone formation, biochemical markers for, 591-595
 - alkaline phosphatase, 591-593
 - osteocalcin, 593-594
 - procollagen peptide, 594-595
 - formation period in, measurement of, 618
 - rate of, measurement of, 618
 - regulation of, 581-585
 - glucocorticoid effects on, 635
 - stimulation of, 738
 - vitamin D and metabolites in, 760-762
- Bone growth, 610
- Bone mass, exercise effects on, 788-789
 - increasing, in established osteoporosis, 737
 - low, definition of, 541-542
 - measurement of, 789
 - peak, calcium intake and, 692-693
 - gender differences in, 673
 - vs. age, 535-536, 542, 693, 700
 - in rheumatoid arthritis, 567
 - vs. age of menopause, 545
 - vs. cardiovascular fitness, 791
 - vs. muscle strength, 791
- Bone modeling, 611
- Bone morphogenetic proteins, in bone remodeling, 583-584
- Bone remodeling, 611-612. See also *Bone formation*; *Bone resorption*.
 - biochemical markers for, 589-607
 - applications of, 591
 - for bone formation, 591-595
 - for bone resorption, 595-602
 - bisphosphonates effects on, 717-719
 - during menstrual cycle, 710
 - exercise effects on, 788-789
 - inhibitors for, 736-737
 - regulatory factors in, 577-588, 743-746
 - formation phase, 581-585
 - resorption phase, 578-581
 - space filling in, agents promoting, 737
 - vitamin D and metabolites in, 760-762
- Bone resorption, biochemical markers for, 595-602
 - collagen telopeptides, 600, 602
 - galactosyl hydroxylysine, 598
 - hydroxyproline, 596-597
 - pyridinoline/deoxypyridinoline, 599-600
 - tartrate-resistant acid phosphatase, 596
- inhibition of, 581
 - in osteoporosis therapy, 745
- regulation of, 578-581
 - bisphosphonates effects on, 718-719
 - cytokines in, 634, 745
 - glucocorticoid effects on, 635-636
 - vitamin D and metabolites in, 760-762
- Bone strength, vs. bone density, 652
- Borreliosis. See *Lyme disease*.
- Brain, occlusive disease of, in antiphospholipid antibody syndrome, 48, 54-55
 - SLE effects on. See *Neuropsychiatric lupus erythematosus*.
- Breast cancer, in estrogen therapy, 705
- Bronchiolitis obliterans and bronchiolitis obliterans organizing pneumonia, in SLE, 175-177
- Bullous lesions, in SLE, 200-202
- Bursitis, trochanteric, vs. lumbar spinal stenosis, 479
- Butorphanol, abuse of, myositis in, 1025
- Butterfly rash, in SLE, 199-200
- Caffeine, myopathy from, 1027
- Calcinosis, in myositis, juvenile, 925-927
 - treatment of, 912
- Calcitonin, in osteoporosis, 683, 777-785
 - in glucocorticoid therapy, 639-641
 - in immobilized patients, 781-782
 - side effects of, 781-782
- Calcitriol, in osteoporosis, 639-640, 697-698
- Calcium, absorption of, in glucocorticoid therapy, 633, 639
 - vitamin D and metabolites in, 762-763
 - vs. age, 693, 763
 - excretion of, in glucocorticoid therapy, 633, 637
 - intake of, gender differences in, 676-678
 - malabsorption of, osteoporosis and, 547
 - supplementation with, in osteoporosis, 639, 692, 694-696, 737
- Calcium carbonate, in osteoporosis
 - prevention, 695
- Calcium citrate malate, in osteoporosis
 - prevention, 695
- Calcium lactogluconate, in osteoporosis
 - prevention, 695
- Calcium pyrophosphate crystals, in synovial fluid, microscopy of, 510
- Calcium-channel blockers, in SLE, in pregnancy, 107
- Cancer, clinical correlates in, 950
 - in cyclophosphamide therapy, 279
 - in estrogen therapy, 705
 - in myositis, 943-953
 - age factors in, 948
 - epidemiology of, 944-946
 - evaluation for, 949-950

- Cancer (*Continued*)
 inclusion body, 964
 interrelationships in, 947-948
 laboratory correlates in, 950
 types of, 948-949
- Carbamazepine, in drug-induced lupus, 69
- Carbimazole, myopathy from, 1027
- Carbonic anhydrase III, measurement of, in myositis, 852
- Carcinogenicity, of methotrexate, 524
- Cardiac arrhythmias, in eosinophilia myalgia syndrome, 979
 in myositis, treatment of, 914
- Cardiolipin antibodies. *See* Anticardiolipin antibodies.
- Cardiovascular disease, estrogen protection against, 705
- Cardiovascular fitness, vs. bone mass, 791
- Cardiovascular system, eosinophilia myalgia syndrome manifestations in, 979
 juvenile myositis effects on, 928
 SLE effects on, in pediatric patients, 122-123
- Carditis, Lyme, 363
- Catastrophic occlusion syndrome, in antiphospholipid antibody syndrome, 49, 55-56
- Central nervous system, eosinophilia myalgia syndrome manifestations in, 977-978
 SLE effects on. *See* Neuropsychiatric lupus erythematosus.
- Cerebellar ataxia, in SLE, 134
- Cerebrospinal fluid, analysis of, in neuropsychiatric lupus, 143
 antibodies in, in SLE, 139
- Cerebrovascular accident. *See* Stroke.
- Chagas' disease, myositis in, 1009-1010
- Chemotherapy, in myositis, 905, 907-908
- Children. *See* Pediatric patients.
- Chlorambucil, in myositis, 907-908
 in SLE, 272, 282
- Chloroquine, in SLE, 253
 adverse reactions to, 255-258
 chemical structure of, 245
 clinical trials of, 249-250, 252
 in pregnancy, 105, 254
 mechanisms of action of, 245-248
 pharmacology of, 244
 myopathy from, 1020
- Chlorpromazine, antiphospholipid antibody syndrome from, 47
 in drug-induced lupus, 69
- Cholesterol levels, estrogen therapy effects on, 705
- Chorea, in SLE, 134
- Chromatin, antibodies to, in SLE, 23-24
- Chronic interstitial lung disease, in SLE, 167-171
- Churg-Strauss syndrome, clinical features of, 417
 diagnosis of, 415, 419, 422
 treatment of, 412
- Cimetidine, myopathy from, 1027
- Claudication, neurogenic, in spinal stenosis, 472-475
- Clodronate, in osteoporosis, 724-725, 728
 chemical structure of, 717
 mechanism of action of, 718-719
 side effects of, 719-720
- Coagulation, in lupus nephritis, 231-233
- Cocaine abuse, myositis in, 1024-1025
- Cogan's syndrome, clinical features of, 417
 diagnosis of, 415, 419-423
- Colchicine, in dermatomyositis, 912
 in SLE, in interstitial lung disease, 171
 myopathy from, 1019-1020
- Collagen, components of, as bone resorption markers, 596-602
 precursors of, as bone resorption markers, 594-595
- Colony-stimulating factors, in bone resorption, 580, 745
- Complement, deficiency of, in SLE, 205
 in drug-induced lupus pathogenesis, 73
- Computed tomography, in arthritis, vs. diagnostic arthroscopy, 324-325
 in inflammatory myopathy, 839
 in neuropsychiatric lupus, 144
 in spinal stenosis, 477-478
 quantitative, in bone density measurement, 658-661, 789
- Congenital heart block, in neonatal lupus, 124-125
- Congestive heart failure, in myositis, treatment of, 913-914
- Consciousness, alterations of, in SLE, 132
- Contraction tests, in fetal assessment, in SLE, 102
- Corticosteroids, in myositis, 902-905, 911-914
 inclusion body, 964-965, 967-968
 in neuropsychiatric lupus, 150
 in SLE, adverse reactions to, antimalarial modulation of, 252
 in bronchiolitis obliterans, 176-177
 in interstitial lung disease, 170-171
 in pneumonitis, 166
 in pregnancy, 103-104
 in pulmonary hemorrhage, 174-175
 in vasculitis, 412-413
 muscle weakness from, 637
 myopathy from, 1018-1019
 osteoporosis from, 549, 629-650
 assessment of, 637-639
 bone histomorphometry in, 632

- characteristics of, 631
- fractures in, 632
- in rheumatoid arthritis, 568, 570, 630
- pathogenesis of, 632-637
 - at cellular level, 634-637
 - systemic effects in, 632-633
- prevention of, 639-642, 727-728
- susceptibility to, 631
- treatment of, 639-642, 711
- Coxsackievirus infections, myositis in, 997-1001
- Cranial neuropathy, in Lyme disease, 364
- in SLE, 133
- C-reactive protein, rheumatoid arthritis prognosis and, 314
- Creatine, measurement of, in myositis, 854
- Creatine kinase, in myositis, 827-828, 846-849
 - inclusion body, 957
 - juvenile, 921, 930, 934, 946
 - vs. therapeutic response, 903-905
- Creatinine, measurement of, in inflammatory myopathy, 836-837
- Cromolyn, myopathy from, 1027
- Cryoglobulinemia, clinical features of, 417
- diagnosis of, 415, 429
- Crystal-induced arthritis, synovial fluid analysis in, 504, 510
- Culture, of synovial fluid, 508-509
- Cutaneous lupus erythematosus, 196-198
 - subacute, 198-199
 - La(SSB) antibodies in, 36-39
 - Ro(SSA) antibodies in, 36-39
- Cyclophosphamide, in lupus nephritis, 235
- in myositis, 907-908
- in neuropsychiatric lupus, 150, 277-278
- in SLE, 265-269, 273-277
 - effects on inflammatory mechanisms and mediators, 268-269
 - effects on lymphocytes, 266-268
 - hemorrhagic cystitis in, 279-280
 - in interstitial lung disease, 171
 - in pediatric patients, 123
 - in pneumonitis, 166
 - in pregnancy, 105-106
 - in pulmonary hemorrhage, 174-175
 - infection incidence in, 280-281
 - malignancy induced by, 279
 - metabolism of, 265-266
 - toxicity of, 278-279
- Cyclosporine, bone loss from, 571
- in myositis, 908, 936
- inclusion body, 965
- in SLE, 272, 285-286
- myopathy from, 1020-1021
- Cystitis, hemorrhagic, in cyclophosphamide therapy, 279-280
- Cytokines. See also *Interferon(s)*; *Interleukin(s)*
- in bone resorption, 579-581
 - glucocorticoid effects on, 634
 - in rheumatoid arthritis, 566-567
 - therapy with, 743-746
- in eosinophilia myalgia syndrome, 983
- in inflammatory myopathy, 889-892
- in lupus nephritis, 237
- inhibition of, antimalarials in, 247
- in osteoporosis therapy, 745
- Cytopenia, in methotrexate therapy, 520-521
- Cytoplasm, antibodies to, in myositis, 860, 866-867
- Deep tendon reflexes, absence of, in spinal stenosis, 476
- Deflazacort, bone loss from, 641-642
- Dementia, in SLE, 132
- Dental problems, in osteoporosis, 539
- Deoxyypyridinoline, as biochemical marker, for bone resorption, 599-600
- Dermatitis, malar, in SLE, 199-200
- Dermatomyositis, antibodies in, myositis-associated, 858, 870-871
 - significance of, 858, 870-871
 - myositis-specific, 858-870
 - significance of, 857-879
- cancer in, 815, 943-953
 - age factors in, 948
 - clinical correlates in, 950
 - epidemiology of, 944-946
 - evaluation for, 949-950
 - interrelationships in, 947-948
 - laboratory correlates in, 950
 - types of, 948-949
- definition of, 813
- diagnostic criteria for, 812
- juvenile. See *Myositis, juvenile*.
- treatment of, 912
- without myositis, definition of, 813
- Diagnostic issues, arthroscopy, 321-342
- computed tomography, 324-325
 - in spinal stenosis, 477-478
- histocompatibility typing, 371-390
- in antiphospholipid antibody diseases, 443-469
- in fibromyalgia, 485-501
- in lumbar spinal stenosis, 471-483
- in Lyme disease, 361-369
- in methotrexate toxicity monitoring, 513-528
- in rheumatoid arthritis prognosis, 309-319
- in Sjogren's syndrome, 391-407
- in synovial fluid analysis, 503-512
- in vasculitis, 409-442

Diagnostic issues (*Continued*)

- magnetic resonance imaging. See *Magnetic resonance imaging*.
- myelography, in spinal stenosis, 477-478
- Dialysis, bone histomorphometry in, 622-624
- Diaphragmatic dysfunction, in SLE, 177-178
- Diarrhea, in eosinophilia myalgia syndrome, 980
- Diazocholesterol, myopathy from, 1023
- Dichloromethylene bisphosphonate. See *Clodronate*.
- Diet, calcium in, 692, 695
- 1,25-Dihydroxyvitamin D, in bone cell differentiation, 762
 - in bone remodeling, 760-762
 - levels of, in glucocorticoid therapy, 634, 639-640
 - vs. age, 765-766
 - supplementation with, in osteoporosis, 768-769
- Diphenylhydantoin, in drug-induced lupus, 69
- Diphosphonates. See *Bisphosphonates*.
- Disability, in rheumatoid arthritis, predictors of, 314-315
- Discoid lupus lesions, 195-198
- Disodium ethane-1-hydroxy-1,1'-bisphosphonate. See *Etidronate*.
- Diuretics, in SLE, in pregnancy, 107
 - thiazide. See *Thiazides*.
- DNA, antibodies to, in drug-induced lupus, 8
 - in lupus nephritis, 229-230
 - in SLE, 2-5, 8
 - double-stranded, antibodies to, in SLE, 2-5
 - drug interactions with, in drug-induced lupus, 73
- DNA methylation, drug-induced lupus and, 74-75
- DNA replication/repair complexes, antibodies to, in SLE, 21-23
- DNA-dependent protein kinase, Ku antigen association with, 16
- Dolorimetry, in fibromyalgia, 494-495
- Doppler studies, in SLE pregnancy, 101-102
- Doxycycline, in Lyme disease, 367
- Drug(s), abuse of, myositis in, 1024-1025
 - antiphospholipid antibody syndrome from, 47
 - myositis from, 817-818. See also *Myositis, drug-induced*.
- Drug-induced lupus, 61-86
 - anti-DNA antibodies in, 8
 - clinical presentation of, 63-66
 - demographics of, 62-63
 - drugs implicated in, 68-71
 - epidemiology of, 62-63
 - genetic factors in, 72-73
 - historical aspects of, 61-62
 - laboratory tests in, 66-68
 - management of, 71-72
 - pathogenesis of, 72-75
- Drug-related inflammatory myopathy, 1017-1032
 - alcohol, 1025
 - anesthetics, 1026
 - antibiotics, 1026
 - cardiac medications, 1025-1026
 - chloroquine, 1020
 - colchicine, 1019-1020
 - corticosteroids in, 1018-1019
 - cyclosporine, 1020-1021
 - gold salts, 1021
 - hydroxychloroquine, 1020
 - in abuse, 1024-1025
 - lipid-lowering drugs, 1023
 - local, from injection, 1026
 - penicillamine, 1020
 - L-tryptophan, 973, 980-982, 1022
 - with hypokalemia, 1023-1024
 - zidovudine, 1021-1022
- Dry eye, in Sjögren's syndrome, 395-401
- Dry mouth, in Sjögren's syndrome, 394, 399, 401, 404
- Dual photon absorptiometry, in bone density measurement, 653-655, 789
- Dual x-ray absorptiometry, in bone density measurement, 655-657, 660, 789
- Dual-energy x-ray absorptiometry, in inflammatory myopathy, 837-838
- Dysphagia, in eosinophilia myalgia syndrome, 980
 - in myositis, 929
 - inclusion body, 966
 - treatment of, 914
- Dyspnea, in myositis, treatment of, 912-913
- Echocardiography, fetal, in SLE, 102
- Echovirus infection, myositis in, 933, 1001-1002
- Effusion, pleural, in SLE, 162-164
- Eicosapentaenoic acid, in lupus nephritis, 237
- EJ antigen, antibodies to, in myositis, 859-860, 862
- Electroencephalography, in neuropsychiatric lupus, 143-144
- Electromyography, in inclusion body myositis, 957-958
 - in inflammatory myopathy, 828
 - in juvenile myositis, 928
 - in spinal stenosis, 478-479

- in vasculitis, 428
- Embolism, pulmonary, in SLE, 182
- Enalapril, myopathy from, 1025-1026
- Endometrial cancer, in estrogen therapy, 705
- Endothelial cells, antibodies to, in myositis, 870
 - function of, in lupus nephritis, 233
- Enteropathic arthritis, HLA typing in, 372
- Enterovirus infections, myositis in, 997
- Enzyme-linked immunosorbent assay, in antiphospholipid antibody syndrome, 52-53
- Eosinophil(s), in eosinophilia myalgia syndrome, 983, 985
- Eosinophilia myalgia syndrome, 973-994
 - clinical manifestations of, 974-980
 - articular, 978
 - cardiac, 979
 - gastrointestinal, 980
 - mucocutaneous, 974-976
 - neuromuscular, 976-978
 - pulmonary, 978-979
 - epidemiology of, 980-981
 - etiology of, 980-982, 1022
 - fibrosis in, 984-986
 - genetic factors in, 982
 - pathogenesis of, 982-986
 - risk factors for, 981-982
- Eosinophilic fasciitis, vs. eosinophilia myalgia syndrome, 975-976
- Epsilon-aminocaproic acid, myopathy from, 1021
- Eroded surface, bone, definition of, 617
- Erythema migrans, in Lyme disease, 362-363
- Erythrocyte complement receptor, in lupus nephritis, 231
- Erythrocyte sedimentation rate, in myositis, 854
 - rheumatoid arthritis prognosis and, 313-314
- Esophageal disorders, in myositis, treatment of, 914
- Estradiol, in osteoporosis, dosage of, 704
- Estrogens, deficiency of, osteoporosis and, 544-545, 678-680, 699-701
 - bisphosphonate prophylaxis in, 726-727
- in bone resorption inhibition, mechanism of, 700-701
- in osteoporosis, 548, 640, 679-680
 - administration methods for, 704
 - bone density effects of, 701-702
 - bone density measurement with, 706
 - discontinuation of, 706-707
 - dosage of, 704
 - efficacy of, 707-708
 - extraskeletal effects of, 705
 - fracture rate and, 704
 - in established disease, 736
 - length of therapy, 703-704
 - waning effect of, 703-704
- levels of, in glucocorticoid therapy, 632, 638, 640
- Estrone sulfate, in osteoporosis, dosage of, 704
- Ethinyl estradiol, in osteoporosis, dosage of, 704
- Ethosuximide, in drug-induced lupus, 69
- 1,1'-Ethylidenebis(tryptophan), eosinophilia myalgia syndrome from, 981
- Etidronate, in osteoporosis, 720-724
 - chemical structure of, 717
 - in glucocorticoid therapy, 641
 - mechanism of action of, 717-719
 - prophylactic, 726-728
 - side effects of, 719-720
- Etofibrate, myopathy from, 1023
- Etretinate, myopathy from, 1027
- Exercise, in osteoporosis prevention, 699, 787-802
 - bone density measurement in, 789
 - bone response mechanism in, 788-789
 - in established disease, 795
 - in middle-aged adults, 793-794
 - in older adults, 794-795
 - in young adults, 792-793
 - unilateral, 790
 - vs. moderate activity, 790-791
 - vs. sedentary controls, 790
- osteoporosis risk and, 546
- gender differences in, 678
- in rheumatoid arthritis, 567-568
- Eye, dryness of, in Sjögren's syndrome, 395-401
 - myositis effects on, 929
 - vasculitis of, 423
- Falls, biomechanics of, 550
 - risk factors for, 549
- Family history, of osteoporosis, 544
- Fasciitis, eosinophilic, vs. eosinophilia myalgia syndrome, 975-976
 - plantar, magnetic resonance imaging in, 354
- Fatigue, in eosinophilia myalgia syndrome, 978
 - in myositis, 911
- Fatty acids, omega-3-unsaturated, in lupus nephritis, 237
- Fenofibrate, myopathy from, 1023
- Fer antigen, antibodies to, in myositis, 816-817, 861, 866
- Fertility, methotrexate effects on, 524
- Fetus, assessment of, in SLE, 100-103

Fetus (*Continued*)

- loss of, in antiphospholipid antibody syndrome, 91-93
- in SLE, 87-91

Fibric acid derivatives, myopathy from, 1023

- Fibrillar, antibodies to, in myositis, 870
- Fibrinolysis, defective, in lupus nephritis, 231-233

Fibrinopeptide, measurement of, in myositis, 931

Fibroblast growth factors, in bone remodeling, 582-583

Fibromyalgia, 485-501

- diagnosis of, 496-499
- confounding conditions in, 497-499
- pain evaluation in, 487, 489-491
- tender points in, 492-495
- model for, 485-486, 488
- signs and symptoms of, 495-496
- typical patient with, 486-487
- Fibrosis, pulmonary, in SLE, 167-171
- Fibrositis, in Lyme disease, 368
- Flecainide, myopathy from, 1025
- Fluoride, in bone remodeling, 584-585
- in osteoporosis therapy, 640, 738
- Fluorochromes, for bone specimen labeling, 614-615

Focal nodular myositis, definition of, 815

Folic acid supplementation, in methotrexate therapy, 515-516

Formation period, measurement of, 618

Fracture threshold, bone density and, 691

Fractures, in osteoporosis, 535

epidemiology of, 536-540, 542-544, 549

calcitonin therapy effects on, 780

estrogen effects on, 704

gender differences in, 671-674

falls in, 549-550

glucocorticoid-induced, 632

in bisphosphonate therapy, 719

pathogenesis of, 540

prevention of, exercise in, 787-788

risk factors for, 539-550

body type, 545-546

demographic, 542-544

diet, 547-548

estrogen deficiency, 548

family history, 544-545

gender, 543-544, 674

lifestyle, 546-547

low bone mass, 541-542

medical conditions and medications, 548-549

non-skeletal, 549-550

racial, 542-543

reproductive history, 544-545

with rheumatoid arthritis, 571-572

- with spondyloarthropathies, 572-573
- repair of, mechanisms for, 612-613

Galactosyl hydroxyllysine, as bone resorption marker, 598

Gamma globulin, intravenous, in myositis, 908-910

Gastrointestinal disorders, in eosinophilia myalgia syndrome, 980

in methotrexate therapy, 516

in myositis, juvenile, 928-929

treatment of, 914

Gemfibrozil, myopathy from, 1023

Gender, osteoporosis and, 543-544, 671-689

aging effects in, 673-676

assessment of, 681-683

body type in, 678

calcium nutrition in, 676-679

fracture incidence, 671-674

gonadal functional changes in, 678-680

peak bone mass and, 673

physical activity in, 678

treatment of, 683-684

rheumatoid arthritis outcome and, 311

Genetic factors, in drug-induced lupus, 72-73

in juvenile myositis, 932

in lupus nephritis, 233

in rheumatoid arthritis outcome prediction, 309-311

Genitourinary system, myositis effects on, 929

Giant cell (temporal) arteritis, biopsy in, 433-434

diagnosis of, 423, 430-434

HLA typing in, 381-382

treatment of, 412

Glomerulonephritis, in SLE, anti-dsDNA antibodies in, 4

diffuse proliferative, 218-219

focal proliferative, 218

membranous, 219

mesangial, 217

in vasculitis, 415

Glucocorticosteroids. *See* Corticosteroids.

Glucose, in synovial fluid, 509

 β_2 -Glycoprotein I, complex with phospholipids, 53

Glycyrrhizin ingestion, myopathy in, 1023-1024

Gold salts, myopathy from, 1021

Gonadotropin-releasing hormone therapy, osteoporosis from, 709-710

Gottron's papules, in dermatomyositis, 921, 944

Graft versus host myositis, 818

- Gram stain, of synovial fluid, 508-509
- Granulocytopenia, in cyclophosphamide therapy, 281
- Granulomatosis, Wegener's. See *Wegener's granulomatosis*.
- Growth abnormalities, in SLE, in pediatric patients, 123
- Growth factors, in bone remodeling, 577-588
 formation phase, 581-585
 glucocorticoid effects on, 634-635
 resorption phase, 578-581
 therapy with, 743-746
- Growth hormone secretion, in glucocorticoid therapy, 633
- Hair, SLE effects on, 203
- Hand, osteoarthritis of, osteoporosis in, 564-565
- Headache, in SLE, 134-135
- Heart, antiphospholipid antibody syndrome effects on, 449
 Lyme disease effects on, 363
 myositis effects on, treatment of, 913-914
 valvular disease of, in antiphospholipid antibody syndrome, 52, 55
 vasculitis affecting, 422, 424
- Heart block, in neonatal lupus, 124-125
- HELLP syndrome, in SLE, 99
- Hematologic toxicity, of methotrexate, 520-521
- Hemiballismus, in SLE, 134
- Hemolysis, in antimalarial therapy, 256
- Hemorrhage, pulmonary, in SLE, 171-175
 in vasculitis, 415
- Hemorrhagic cystitis, in cyclophosphamide therapy, 279-280
- Henoch-Schönlein purpura, clinical features of, 417
 diagnosis of, 414-416
 treatment of, 412
- Heparin, in antiphospholipid antibody syndrome, 54-55
 in pregnancy, 108
 interference by, in lupus anticoagulant detection, 457
- Hepatitis B, myositis in, 1004
- Hepatomegaly, in eosinophilia myalgia syndrome, 980
- Hepatotoxicity, of methotrexate, 516-520
- Hip, osteoarthritis of, osteoporosis in, 562-566
 vs. lumbar spinal stenosis, 479
 transient osteoporosis of, magnetic resonance imaging in, 346, 352
- Hip fractures, in osteoporosis, epidemiology of, 536-540, 543
 gender differences in, 671-672
 fall biomechanics and, 550
- Histocompatibility typing. See *Human leukocyte antigens, typing of*.
- Histomorphometry, bone, 616-624
 in osteomalacia, 619-622
 in osteoporosis, 619, 632, 682-683
 in renal osteodystrophy, 621-624
 parameters of, 616-618
- Histones, antibodies to, in drug-induced lupus, 67-68
 in SLE, 5, 7-8
- HLA. See *Human leukocyte antigens*.
- Hormones. See also *Estrogens; Testosterone*.
 levels of, in glucocorticoid therapy, 632, 634, 638, 640
- Human immunodeficiency virus infection, antiphospholipid antibody syndrome from, 47
 myositis in, 818, 1002-1003
- Human leukocyte antigens, classes of, 371
 in drug-induced lupus pathogenesis, 72-73
 in eosinophilia myalgia syndrome, 982
 in myositis, 865-866, 872
 in pediatric patients, 932
 processing of, antimalarial effects on, 245-247
 typing of, 371-390
 clinical uses of, 372
 HLA-B27, 372-376
 HLA-DR alleles, 376-379
 in connective tissue diseases, 381-382
 in juvenile rheumatoid arthritis, 379-380
 in Lyme disease, 380
 in pediatric patients, 375
 in rheumatoid arthritis, 309-311, 376-379
 in spondyloarthropathy, 372-376
 in vasculitis, 381-382
- Human T-cell lymphotropic virus infection, myositis in, 1003-1004
- Hydralazine, in drug-induced lupus, 63-65
 antibodies to, 68
 DNA interactions with, 73
 genetic factors in, 72-73
 immunoregulatory abnormalities in, 74
 laboratory findings in, 68
 in SLE, in pregnancy, 106-107
- Hydroxychloroquine, in dermatomyositis, 912
 in Sjögren's syndrome, 252
 in SLE, 253-254
 adverse reactions to, 254-258
 chemical structure of, 245
 clinical trials of, 249-252
 in pregnancy, 105, 254
 mechanisms of action of, 245-248

- Hydroxychloroquine (*Continued*)
 pharmacology of, 244
 myopathy from, 1020
- Hydroxyproline, as bone resorption marker, 596-597
- 1 α -Hydroxyvitamin D, supplementation with, in osteoporosis, 769
- Hypercalciuria, in glucocorticoid therapy, 633, 639-640
- Hypercholesterolemia, in lupus nephritis, 236
 in SLE, antimalarial effects on, 252
- Hyperparathyroidism, in glucocorticoid therapy, 632-633, 639-640
 osteoporosis in, 548-549
 treatment of, 698-699
- Hypersensitivity vasculitis, 411-416
- Hypertension, in SLE, in pregnancy, treatment of, 106-107
 pulmonary, in SLE, 178-181
- Hyperthermia, malignant, myopathy in, 1026
- Hyperthyroidism, myopathy in, 1027
 osteoporosis in, 549
- Hypocomplementemia, in SLE, 205
- Hypogammaglobulinemia, X-linked, juvenile myositis in, 933
- Hypogonadism, osteoporosis in, gender differences in, 679-680
- Hypokalemia, in corticosteroid therapy, 1019
 myopathy in, 1023-1024
- Hypophosphatemia, myopathy in, 1024
- Hypothyroidism, myopathy in, 1027
- Ilium, biopsy of. *See Bone biopsy, transilial.*
- Immobilization, osteoporosis in, calcitonin therapy for, 777-778
 prevention of, 728
 risk of, 546
- Immune complexes, in lupus nephritis, 229-231
 in myositis, 855, 931
- Immunodeficiency, juvenile myositis in, 933
 myositis in, 818
- Immunoglobulins, intravenous, in myositis, 908-910, 936
- Immunoregulation, abnormalities in, in drug-induced lupus, 74
- Immunosuppressive therapy, in myositis, 905, 907-908
 inclusion body, 967-968
 in SLE, 265-299
 azathioprine. *See Azathioprine.*
 chlorambucil, 272, 282
 combination regimens, 286-287
 cyclophosphamide. *See Cyclophosphamide.*
 cyclosporine, 272, 285-286
 in pregnancy, 105-106
 methotrexate, 166-167, 271-272, 284-287
 nitrogen mustard, 281-282
- Inclusion(s), amyloidogenic protein, in inclusion body myositis, 961
 microtubular filamentous, in inclusion body myositis, 959-961
- Inclusion body myositis. *See under Myositis.*
- Indomethacin, in SLE, in pregnancy, 104
- Infections, antiphospholipid antibody syndrome in, 47
 in cyclophosphamide therapy, 280-281
 in SLE, in pediatric patients, 120-121
 respiratory, 182, 184
 myositis in, 817-818, 995-1015
 adenovirus in, 962
 agents causing, 995-996
 antibodies associated with, 871-873
Borrelia burgdorferi in, 1010-1011
 coxsackieviruses in, 997-1001
 echoviruses in, 933, 1001-1002
 encephalomyocarditis virus in, 1002
 enteroviruses in, 997
 helminth, 1010
 hepatitis B virus in, 1004
 human immunodeficiency virus in, 1002-1003
 human T-cell lymphotropic virus in, 1003-1004
 inclusion body, 962-963
 juvenile, 924, 933
 mechanisms in, 995-997
 mumps virus in, 962-963, 1004
 paramyxoviruses in, 962-963
 protozoan, 1004-1010
 retroviruses in, 1002-1004
 spirochetal, 1010-1011
Toxoplasma gondii in, 1004-1009
Trichinella in, 1010
Trypanosoma cruzi in, 1009-1010
- Inflammatory arthritis, diagnostic arthroscopy in, 326-331
- Inflammatory myopathy. *See also Myositis; specific disease.*
 autoimmune mechanisms in, 857-879
 cancer and, 815, 943-953
 classification of, 811-826
 clinicopathologic, 813-816
 serologic, 816-817
 cytokines in, 889-892
 differential diagnosis of, 900-901
 drug-related, 1017-1032
 environmentally-associated, 817-818
 eosinophilic myalgia syndrome, 973-994

- histopathology of, 881-897
 human leukocyte antigens in, 865-866, 872
 hypokalemic, 1023-1024
 in hypophosphatemia, 1024
 in pediatric patients, 919-942
 inclusion bodies in, 955-972
 infections in. See *Infections, myositis in*.
 laboratory tests for, 845-856
 lymphocyte subsets in, 886-887
 lymphocyte-mediated myotoxicity in, 888-889
 major histocompatibility complex expression in, 885-886
 neuromuscular functional evaluation in, 827-843
 overlap among syndromes, 812
 prognosis for, 818, 820-821
 treatment of, 899-917
 physical therapy in, 901
 principles of, 900-901
 Injection, of drugs, myopathy from, 1026
 Insulin-like growth factors, in bone remodeling, 583
 glucocorticoid effects on, 634-635
 therapy with, 745
 Integrins, in bone resorption, 578
 Intercellular adhesion molecules, in inflammatory myopathy, 891
 Interferon(s), drug-induced lupus from, 70-71
 inhibition of, antimalarials in, 247
 Interferon alpha, drug-induced lupus from, 70-71
 Interferon gamma, drug-induced lupus from, 70-71
 in bone resorption inhibition, 581
 in inflammatory myopathy, 889-892
 Interleukin(s), in eosinophilia myalgia syndrome, 984-986
 in inflammatory myopathy, 887, 889, 891
 in rheumatoid arthritis, bone loss from, 566
 inhibition of, antimalarials in, 247
 Interleukin-1, in bone resorption, 579, 745
 glucocorticoid effects on, 634
 Interleukin-1 receptor antagonist, in bone resorption inhibition, 581
 Interleukin-6, in bone resorption, 580-581, 745
 glucocorticoid effects on, 634
 Intermediary organization of skeleton concept, 610-613
 Interstitial lung disease, chronic, in SLE, 167-171
 in myositis, 859
 treatment of, 913
 Irradiation. See *Radiation therapy*.
 Isoniazid, in drug-induced lupus, 69
 genetic factors in, 72
 Isotretinoin, in dermatomyositis, 912
 myopathy from, 1027
 Janeway's spots, in SLE, 204
 Jo-1 antigen, antibodies to, in myositis, 858-860, 862, 864-865
 Juvenile myositis. See under *Myositis*.
 Juvenile rheumatoid arthritis, HLA typing in, 375, 379-380
 Kaolin clotting time, in lupus anticoagulant detection, 456
 Kawasaki disease, clinical features of, 417
 diagnosis of, 419, 422
 treatment of, 413
 Keratoconjunctivitis sicca, in Sjögren's syndrome, 395-401
 Ketoconazole, myopathy from, 1026
 Kidney, biopsy of, in SLE, 223-224, 226-228
 dysfunction of, in drug-induced lupus, 65-66
 failure of, bone histomorphometry in, 621-624
 SLE effects on. See also *Lupus nephritis*.
 anti-dsDNA antibodies and, 4
 in pediatric patients, 121-122
 in pregnancy, 90-91, 94, 98-100
 thromboses in, in antiphospholipid antibody syndrome, 49
 vasculitis of, 426, 429
 KJ antigen, antibodies to, in myositis, 816-817, 860, 866
 Ku antigen, antibodies to, in myositis, 816-817, 870
 in SLE, 14-21
 function of, 14-16
 structure of, 14-16
 La(SSB) antigen, antibodies to, in cutaneous lupus erythematosus, 36-39
 in neonatal lupus, 37-38, 124-125
 in Sjögren's syndrome, 38-39
 in Sjögren's syndrome, 405
 structure of, 34-36
 Labetalol, in SLE, in pregnancy, 106-107
 myopathy from, 1025
 Laboratory testing, in myositis. See under *Myositis*.
 Lactate dehydrogenase, in synovial fluid, 509

- Lactate dehydrogenase (*Continued*)
 measurement of, in myositis, 850-851,
 921, 934
- Lavage effect, in diagnostic arthroscopy,
 322
- Leucovorin supplementation, in
 methotrexate therapy, 515-516
- Leukapheresis, in myositis, 909
- Leukocyte-function associated antigen, in
 inflammatory myopathy, 891
- Leukocytoclastic angiitis, diagnosis of, 415-
 416
 treatment of, 412
- Leukopenia, in methotrexate therapy, 520
- Leuprolide, myopathy from, 1027
 osteoporosis from, 709-710
- Libman-Sacks-type vegetations, in
 antiphospholipid antibody syndrome,
 52
- Licorice ingestion, myopathy in, 1023-1024
- Lined vacuoles, in inclusion body myositis,
 958-959
- Lipid-lowering drugs, myopathy from,
 1023
- Lipoprotein levels, estrogen therapy effects
 on, 705
- Livedo reticularis, in antiphospholipid
 antibody syndrome, 52, 55, 448-449
 in SLE, 205-206
- Liver, methotrexate toxicity to, 516-520
- Lovastatin, myopathy from, 1023
- Lumbar spinal stenosis, 471-483
 definition of, 472-473
 diagnosis of, differential, 479-481
 historical findings in, 474-475
 neurophysiologic testing in, 478-479
 physical findings in, 475-476
 radiologic findings in, 476-478
 etiology of, 480
 pain syndromes with, 480-481
- Lung, hemorrhage of, in vasculitis, 415
 methotrexate toxicity to, 521-524
- Lupoid sclerosis, 135
- Lupus, drug-induced. See *Drug-induced
 lupus*.
 systemic. See *Systemic lupus erythemato-
 sus*.
- Lupus anticoagulant, 444-445
 detection of, 454-457
 in antiphospholipid antibody syndrome,
 45, 449-450
 in normal subjects, 450-451
 in pregnancy, 50, 91-92
 in systemic lupus erythematosus, 451-
 452
 laboratory tests for, 53
 pulmonary embolism and, 182
 vs. anticardiolipin antibodies, 446-448
- Lupus band test, in SLE, 209
- Lupus erythematosus, cutaneous, 36-39,
 196-199
 neonatal. See *Neonatal lupus erythemato-
 sus*.
 neuropsychiatric. See *Neuropsychiatric lu-
 pus erythematosus*.
- Lupus erythematosus cells, in pleural fluid,
 163
- Lupus nephritis, 213-242
 activity/chronicity indices in, 221-222
 azathioprine in, 282-284
 classification of, 213-222
 cyclophosphamide in, 274-277
 cyclosporine in, 285-286
 diffuse proliferative glomerulonephritis,
 218-219
 evaluation of, 222-224
 focal proliferative glomerulonephritis,
 218
 genetic factors in, 233
 histologic transformation of, 220
 immunopathogenesis of, 228-234
 in pediatric patients, 121-122
 in pregnancy, 99-100
 membranous glomerulonephritis, 219
 mesangial glomerulonephritis, 217
 minimal change disease, 216
 nitrogen mustard in, 282
 presentation of, 222
 prognosis for, 224-228
 treatment of, 234-237
- Lyme disease, antiphospholipid antibody
 syndrome from, 47
 diagnosis of, 361-369, 424
 arthritic, 364-365
 confusion in, 361-362, 367-368
 early disseminated, 363-364
 early localized (erythema migrans),
 362-363
 late, 364-365
 neurologic, 364-365
 serologic, 365-366
 with carditis, 363
 fibrositis after, 368
 HLA typing in, 380
 in pregnancy, 367
 myositis in, 1010-1011
 treatment of, 366-368
- Lymphadenopathy, hilar, in SLE, 184
- Lymphocytes. See also *T lymphocytes*.
 azathioprine effects on, 270-271
 cyclophosphamide effects on, 266-268
- Lymphocytotoxic antibodies, in drug-
 induced lupus, 68
- Lymphoid irradiation, in SLE, 286
- Lymphotoxin, in bone resorption, 579
- Macrophage colony-stimulating factors, in
 bone resorption, 580

- Magnetic resonance imaging, 343-360
 in arthritis, vs. diagnostic arthroscopy, 324-325
 in avascular necrosis, 345-346, 351
 in inflammatory myopathy, 838-839
 in myopathy, 346, 355, 358
 in neuropsychiatric lupus, 144-146
 in osteoarthritis, 348
 in osteochondritis dissecans, 345, 350
 in osteomyelitis, 349
 in pigmented villonodular synovitis, 349
 in rheumatoid arthritis, 346-347, 358
 in sacroiliitis, 348
 in sarcoid, 356
 in seronegative spondyloarthropathy, 347-348, 352-353, 357
 in Sjögren's syndrome, 348
 in spinal stenosis, 477-478
 in transient hip osteoporosis, 346, 352
 patient experience with, 344-345
 principles of, 344
 vs. other imaging modalities, 344
 Major histocompatibility complex. See also *Human leukocyte antigens*.
 expression of, in inflammatory myopathy, 885-886
 genes of, 372
 Malabsorption, in eosinophilia myalgia syndrome, 980
 in myositis, 929
 treatment of, 914
 osteoporosis in, 548-549
 Malar dermatitis, in SLE, 199-200
 Malignancy. See *Cancer*.
 Malignant hyperthermia, myopathy in, 1026
 Mas antigen, antibodies to, in myositis, 816-817, 861, 866
 Medroxyprogesterone acetate, in osteoporosis, 640, 710-711
 dosage of, 704
 gonadotropin-releasing hormone-induced, 709
 Meningitis, aseptic, in SLE, 135
 Meningoencephalitis, in Lyme disease, 364
 Menopause, age of, vs. bone mass, 545
 bone loss after, rate of, 678-680, 694-695, 699-700
 calcium supplementation after, 695, 699
 vitamin D and metabolite levels after, 763, 765
 Menstrual cycle, bone remodeling during, 710
 Meperidine, abuse of, myositis in, 1025
 Methotrexate, bone loss from, 571
 carcinogenic potential of, 524
 in myositis, 905, 907-908, 910-911
 inclusion body, 965-966, 968
 juvenile, 936
 in SLE, 166-167, 271-272, 284-287
 in pneumonitis, 166-167
 pharmacology of, 514-516
 toxicity of, 513-528
 gastrointestinal, 516
 hematologic, 520-521
 hepatic, 516-520
 in pregnancy, 524
 mechanisms of, 514-516
 minor reactions in, 516
 neurologic, 516
 pulmonary, 521-524
 to fetus, 524
 Methylation, DNA, drug-induced lupus and, 74-75
 Methyldopa, in SLE, in pregnancy, 106-107
 Methylprednisolone, in myositis, 905
 juvenile, 936
 in neuropsychiatric lupus, 150
 in SLE, in pneumonitis, 166
 in pulmonary hemorrhage, 174
 Mi-2 antigen, antibodies to, in myositis, 816-817, 860, 867
 Microscopy, polarizing, in synovial fluid analysis, 510
 Microtubular filamentous inclusions, in inclusion body myositis, 959-961
 Mikulicz syndrome, 392-393
 Mineral appositional rate, measurement of, 618
 Mineralization lag time, measurement of, 618
 Mineralizing surface, measurement of, 617-618
 Minimal change disease, in SLE, 216
 Minoxidil, myopathy from, 1027
 Mixed connective tissue disease, anti-Ku antigen antibodies in, 17
 Sm/U₁RNP antibodies in, 32-33
 Molecular mimicry, by myositis-associated antibodies, 872
 Monoclonal antibodies, in lupus nephritis treatment, 237
 Mononeuritis multiplex, in vasculitis, 425
 Mood/anxiety syndrome, organic, in SLE, 132-133
 Mortality, in rheumatoid arthritis, predictors of, 315-317
 Mouth, dryness of, in Sjögren's syndrome, 394, 399, 401, 404
 Movement disorders, in SLE, 134
 Mucin clot test, on synovial fluid, 510-511
 Mucinosi, cutaneous, in SLE, 208
 Mumps, myositis in, 1004
 inclusion body, 962-963
 Muscle, abscess of, magnetic resonance imaging in, 358
 biopsy of, in inflammatory myopathy, 828

Muscle (*Continued*)

- evaluation of, in inflammatory myopathy, 827-843
- glucocorticoid effects on, 637
- inflammatory disease of. *See Inflammatory myopathy; Myositis; specific disease.*
- ischemia of, in vasculitis, 425
- mass of, measurement of, in inflammatory myopathy, 835-837
- strength of, testing of, in inflammatory myopathy, 830-835, 840
- vs. bone mass, 791
- Myalgia, in drug-induced lupus, 64
- in eosinophilia myalgia syndrome, 976
- Myasthenia gravis, in SLE, 136
- Myelitis, transverse, in SLE, 133-134
- Myelography, in spinal stenosis, 477-478
- Myocarditis, in myositis, treatment of, 913-914
- Myofasciitis, magnetic resonance imaging in, 355
- Myoglobin, antibodies to, in myositis, 871
- measurement of, in myositis, 853-854
- Myometric testing, in inflammatory myopathy, 832-835
- Myopathy, inflammatory. *See Inflammatory myopathy; Myositis; specific disease.*
- magnetic resonance imaging in, 346, 355, 358
- Myosin, antibodies to, in myositis, 871
- Myositis. *See also Dermatomyositis; Polymyositis.*
 - drug-related, 817-818, 1017-1032
 - focal nodular, definition of, 815
 - graft versus host, 818
 - in infections. *See Infections, myositis in.*
 - inclusion body, 955-972
 - atypical, 966-967
 - cancer in, 943, 964
 - clinical features of, 956-957
 - definition of, 815
 - diagnosis of, 966-967
 - diseases associated with, 963-964
 - electromyography in, 957-958
 - epidemiology of, 956
 - etiology of, 961-963
 - historical background of, 955-956
 - laboratory findings in, 957-961
 - natural history of, 964-966
 - pathology of, 958-961
 - treatment of, 910, 964-968
 - juvenile, 919-942
 - antibodies in, 932-933
 - clinical presentation of, 924-930
 - course of, 936-937
 - definition of, 814-815
 - diagnostic criteria for, 920-922
 - differential diagnosis of, 933-935
 - epidemiology of, 922-924
 - genetic studies in, 932
 - immunodeficiency and, 933
 - pathophysiology of, 930-931
 - treatment of, 935-937
 - laboratory testing in, 845-856
 - aldolase, 849-850
 - aminotransferases, 851-852
 - carbonic anhydrase III, 852
 - creatine, 854
 - creatine kinase, 846-849
 - lactate dehydrogenase, 850-851
 - myoglobin, 853-854
 - orbital, 815
 - primary idiopathic, definition of, 813
 - toxin-induced, 817-818
 - treatment of, corticosteroids in, 902-905
 - extramuscular manifestations, 911-914
 - gamma globulin in, 908-909
 - immunosuppressive drugs in, 905, 907-908
 - irradiation in, 909-910
 - leukapheresis in, 909
 - photochemotherapy in, 910
 - plasmapheresis in, 909
 - thymectomy in, 910
- Myositis ossificans, definition of, 816
- Myositis-associated antibodies, 816-817, 858, 870-871
 - in diagnosis, 899-900
 - significance of, 871-874
- Myositis-scleroderma overlap syndrome, antibodies in, 869
- Myositis-specific antibodies, 816-817
 - in diagnosis, 899-900
- Myxoma, atrial, diagnosis of, 422
- Nafarelin, with gonadotropin-releasing hormone, in osteoporosis prevention, 709
- Nail disorders, in SLE, 208
- Nalidixic acid, myopathy from, 1026
- Nandrolone decanoate, in osteoporosis therapy, 640
- Necrosis, avascular, from glucocorticoids, 636-637
 - magnetic resonance imaging in, 345-346, 351
- Needle injury, myopathy from, 1026
- Neonatal lupus erythematosus, 124-125
 - cutaneous lesions in, 200
 - pathogenesis of, 37-38
- Nephritis, in drug-induced lupus, 65-66
 - in SLE. *See Lupus nephritis.*
- Nerve conduction testing, in spinal stenosis, 478-479

- Nerve root compression, in spinal stenosis, 473, 480
- Neurogenic claudication, in spinal stenosis, 472-475
- Neurologic disorders, in Lyme disease, 364-365
in methotrexate therapy, 516
in vasculitis, 424-425
- Neuromuscular evaluation, in inflammatory myopathy, 827-843
- Neuromyopathy, in chloroquine therapy, 255-256
- Neurons, antibodies to, in SLE, 138-139, 143
- Neurophysiologic testing, in spinal stenosis, 478-479
- Neuropsychiatric lupus erythematosus, 129-158
antineuronal autoantibodies in, 138-139
clinical manifestations of, 130-137
central nervous system, 131-135
peripheral nervous system, 135-136
secondary causes of, 136-137
diagnosis of, 140-148
diagnostic criteria for, 129-130
drug-induced, 66
in pediatric patients, 122
pathogenesis of, 138-140
pathology of, 137-138
prognosis of, 151
treatment of, 148-151, 277-278
vascular occlusion in, 139-140
- Newsprint test, on synovial fluid, 510
- Nicotinic acid, myopathy from, 1023
- Nifedipine, in myositis, 912
- Nitrogen mustard, in SLE, 281-282
- Nodules, in SLE, cavitating, of lung, 184
rheumatoid, 208-209
subcutaneous, rheumatoid arthritis prognosis and, 312-313
- Nonsteroidal antiinflammatory drugs, bone loss from, 571
in SLE, in pregnancy, 104-105
- Nonstress tests, fetal, in SLE, 102
- Norethisterone, in osteoporosis, 710
gonadotropin-releasing hormone-induced, 709
- Nuclear magnetic resonance spectroscopy, in neuropsychiatric lupus, 146
- Nucleocapsids, viral, inclusion body myositis and, 962-963
- Nucleosomes, antibodies to, in SLE, 5, 7-8
- Numbness, in spinal stenosis, 475
- Occlusive disease, vascular, in antiphospholipid antibody syndrome, 48-50, 54-55
- OJ antigen, antibodies to, in myositis, 859-860, 862, 864-865
- Omega-3-unsaturated fatty acids, in lupus nephritis, 237
- Omeprazole, myopathy from, 1027
- Oophorectomy, bone loss after, 701
- Opportunistic infections, in SLE, respiratory, 184
- Oral mucosa, ulceration of, in SLE, 207-208
- Orbital myositis, 815
- Organic brain syndrome, in SLE, 131-132
- Organic mood/anxiety syndrome, in SLE, 132-133
- Osler nodes, in SLE, 204
- Osteitis fibrosa, in renal osteodystrophy, bone histomorphometry in, 621-622
- Osteoarthritis, diagnostic arthroscopy in, 335-336
hip, vs. lumbar spinal stenosis, 479
magnetic resonance imaging in, 348
osteoporosis in, 562-566
of hand, 564-565
of hip, 562-564
- Osteoblast(s), in bone formation, biochemical markers for, 591-595
regulation of, 581-585
glucocorticoid effects on, 635
- Osteoblast surface, definition of, 617
- Osteocalcin, as biochemical marker, for bone formation, 593-594
measurement of, in glucocorticoid therapy, 637-638
- Osteochondritis dissecans, magnetic resonance imaging in, 345, 350
- Osteoclast(s), in bone resorption, regulation of, 578-581
bisphosphonates effects on, 718-719
glucocorticoid effects on, 635-636
- Osteoclast surface, definition of, 617
- Osteodystrophy, renal, bone histomorphometry in, 621-624
- Osteoid surface, measurement of, 617
- Osteoid thickness, measurement of, 617
- Osteomalacia, bone histomorphometry in, 619-622
- Osteomyelitis, magnetic resonance imaging in, 349
- Osteonecrosis, in glucocorticoid therapy, 636-638
- Osteoporosis, age-related, 673-676, 693, 699-700
assessment of, bone biopsy in, 609-627
bone density measurement in, 651-669
bone histomorphometry in, 619, 632, 682-683
clinical findings in, 735-736
- Obesity, fracture risk and, 546

Osteoporosis (Continued)

- gender differences in, 681-683
- glucocorticoid-induced, 637-639
- bone metabolism in, assessment of, biochemical markers for, 589-607
- bone remodeling and, regulatory factors for, 577-588
- definition of, 535
- differential diagnosis of, 682-683
- epidemiology of, 535-559
 - impact of, 536-539
 - risk factors in, 539-550
- established, treatment of, 735-758, 795
- exercise and. *See Exercise.*
- fractures in. *See Fractures.*
- gender differences in, 671-689
- glucocorticoid-induced. *See Glucocorticoids, osteoporosis from.*
- heterogeneity in, 671-689
 - aging and, 673-674
 - assessment, 681-683
 - fracture incidence, 671-674
 - hypogonadism, 679-680
 - medical conditions and medications affecting, 680-681
 - peak bone mass, 673
 - senile type, 674-679
 - treatment, 683-684
- impact of, 536-539
- in immobilizing spondylitis, 572-573
- in immobilization, calcitonin therapy for, 777-778
 - prevention of, 728
 - risk of, 546
- in osteoarthritis, 562-566
- in psoriatic arthritis, 573
- in rheumatic disease, 561-576
- in rheumatoid arthritis. *See Rheumatoid arthritis, osteoporosis in.*
- in spondyloarthropathies, 572-573
- prevention of, 540. *See also Estrogens.*
- bisphosphonates in, 726-728
- calcium supplementation in, 639, 692, 694-696
- exercise in, 699
- in glucocorticoid therapy, 639-642, 727-728
- in immobilization, 728
- progestins in, 708-711
- thiazides in, 548, 639-640, 698-699
- vitamin D in, 639, 697-698
- radiography of, in glucocorticoid therapy, 638
- reversal of, 735-758
- risk factors for, 539-550, 680-681, 692-693
 - body type, 545-546, 678
 - calcium deficiency, 677-679
 - demographic, 542-544

- diet, 547-548
- estrogen deficiency, 544-545, 548, 678-680, 699-701
- family history, 544-545
- gender, 543-544
- gonadotropin-releasing hormone therapy, 709-710
- in glucocorticoid therapy. *See Glucocorticoids, osteoporosis from.*
- lifestyle, 546-547, 678
- low bone mass, 541-542, 673
- medical conditions and medications, 548-549, 680-681
- nonskeletal, 549-550
- racial, 542-543
- reproductive history, 544-545
- senile, heterogeneity in, 674-679
- transient, of hip, magnetic resonance imaging in, 346, 352
- treatment of, 691-716
 - age-related, 693
 - bisphosphonates in, 641, 683-684, 717-734
 - bone formation stimulation in, 738
 - bone resorption inducers in, 745
 - bone turnover slowing in, 736-737
 - calcitonin in, 639-641, 683, 777-785
 - calcium in, 639, 692-696, 699, 737
 - established, 735-758, 795
 - estrogens in. *See Estrogens, in osteoporosis.*
 - exercise in, 699, 787-802
 - fluoride in, 640, 738
 - fracture threshold concept and, 691
 - gender differences in, 683-684
 - glucocorticoid-induced, 639-642, 711
 - growth factors in, 743-746
 - heterogeneity in, 683-684
 - in established disease, 735-758
 - bone formation stimulation in, 738
 - bone resorption inducers in, 745
 - bone turnover slowing in, 736-737
 - growth factors in, 743-746
 - parathyroid hormone in, 740-743
 - prostaglandins in, 738-740
 - space filling in, 737
 - parathyroid hormone in, 740-743
 - progesterone in, 708-711
 - prostaglandins in, 738-740
 - space filling in, 737
 - testosterone replacement in, 640, 678-680
 - thiazide diuretics in, 548, 639-640, 698-699
 - vitamin D and metabolites in, 697-698, 736, 759-775
- type I (estrogen-deficient), 699-700
- type II (age-related), 673-676, 693, 699-700

- Ovarian failure, bone loss after, 701
- Pacemaker, in myositis, 914
- Paget's disease of bone, bone resorption in, cytokine activity in, 580
- Pain, in fibromyalgia, amplification of, 486
evaluation of, 487, 489-491
- Pamidronate, in osteoporosis, 725-726
chemical structure of, 717
gender differences in, 683-684
mechanism of action of, 718-719
prophylactic, 727-728
side effects of, 719-720
- Pancytopenia, in methotrexate therapy, 520-521
- Panniculitis, lupus, 202-203
- Paramyxoviruses, inclusion body myositis and, 962-963
- Paraneoplastic syndrome, Henoch-Schönlein purpura as, 415
myositis as, 948
- Parathyroid hormone, excess of. See *Hyperparathyroidism*.
- in bone remodeling, 584
in osteoporosis therapy, 740-743
- Paresthesia, in spinal stenosis, 475
- Parkinsonism, in SLE, 134
- PCNA (proliferating cell nuclear antigen), antibodies to, in SLE, 22-23
- Pediatric patients, HLA typing in, 375
inflammatory myopathy in, 919-942
antibodies in, 932-933
clinical presentation of, 924-930
diagnostic criteria for, 920-922
differential diagnosis of, 933-935
epidemiology of, 922-924
genetic studies in, 932
immunodeficiency and, 933
pathophysiology of, 930-931
treatment of, 935-937
systemic lupus erythematosus in, 119-127. See also *Neonatal lupus erythematosus*.
treatment of, 276
- Pemphigus, with SLE, 202
- D-Penicillamine, bone loss from, 571
in drug-induced lupus, 69-70
myositis from, 818, 1020
- Penicillin, myopathy from, 1026
- Pentazocine, abuse of, myositis in, 1025
- Pericarditis, in drug-induced lupus, 65
- Peripheral neuropathy, in eosinophilia myalgia syndrome, 977
in Lyme disease, 364
in SLE, 135
- 3-(Phenylamino)alanine, eosinophilia myalgia syndrome from, 981
- Phenylbutazone, myopathy from, 1021
- Phenytoin, myopathy from, 1027
- Phospholipids, antibodies to. See *Antiphospholipid antibody(ies)*.
- Phosphorus, excretion of, in glucocorticoid therapy, 633
- Photochemotherapy, in myositis, 910
- Photosensitivity, in SLE, 206-207
- Physical activity. See *Exercise*.
- Physical therapy, in inflammatory myopathy, 901
- Picornavirus infections, myositis in, 997, 1002
- Pigmented villonodular synovitis, magnetic resonance imaging in, 349
- Piriformis syndrome, vs. lumbar spinal stenosis, 479
- Pivampicillin, myopathy from, 1026
- PL-7 antigen, antibodies to, in myositis, 859-860, 862, 864
- PL-12 antigen, antibodies to, in myositis, 859-860, 862
- Plantar fasciitis, magnetic resonance imaging in, 354
- Plasmapheresis, in myositis, 909
in SLE, in pneumonitis, 166
in pulmonary hemorrhage, 174-175
with cyclophosphamide, 286
- Platelet(s), activation of, in lupus nephritis, 232
- Platelet neutralization procedure, in lupus anticoagulant detection, 457
- Platelet-derived growth factors, in bone remodeling, 583
in eosinophilia myalgia syndrome, 984
- Pleural disorders, in drug-induced lupus, 64
in SLE, 162-164
- PM-1 antigen, antibodies to, in myositis, 932
- PM-Scl antigen, antibodies to, in myositis, 816-817, 861, 869-870
- Pneumonitis, in methotrexate therapy, 521-524
in SLE, 165-167
- Polarizing microscopy, in synovial fluid analysis, 510
- Polyangiitis, clinical features of, 417
diagnosis of, 415, 418-419
treatment of, 412
- Polyarteritis nodosa, clinical features of, 417
diagnosis of, 416, 418, 425-426, 428-429
treatment of, 412
- Polymyalgia rheumatica, in giant cell arteritis, 432-433
- Polymyositis, antibodies in, myositis-associated, 858, 870-871
significance of, 858, 870-871

Polymyositis (Continued)

- myositis-specific, 858-870
- significance of, 857-879
- cancer in, 815, 943-953
 - age factors in, 948
 - clinical correlates in, 950
 - epidemiology of, 944-946
 - evaluation for, 949-950
 - laboratory correlates in, 950
 - types of, 948-949
- definition of, 813
- diagnostic criteria for, 812
- HLA typing in, 381
- juvenile. *See* *Myositis, juvenile*.
- Polyneuropathy, in SLE, 135
- Positron emission tomography, in neuropsychiatric lupus, 146
- Postpolio syndrome, inclusion body myositis and, 963
- Potassium, total body, measurement of, in inflammatory myopathy, 837
- Pravastatin, myopathy from, 1023
- Prazosin, in myositis, 912
- Prednisone, in antiphospholipid antibody syndrome, 54
 - in pregnancy, 108
 - in drug-induced lupus, 71
 - in myositis, 902-905, 907-908, 910-911
 - inclusion body, 968
 - in rheumatoid arthritis, osteoporosis from, 568, 570
 - in SLE, in interstitial lung disease, 171
 - myopathy from, 1018-1019
- Preeclampsia, vs. lupus nephropathy, 99-100
- Pregnancy, anticardiolipin antibodies in, 92
- antiphospholipid antibody syndrome and, 50, 54
 - fetal loss in, 91-93
 - preterm delivery in, 94
 - treatment of, 107-108
- lupus anticoagulant in, 91-92
- Lyme disease in, 367
- methotrexate therapy in, 524
- problems with, in antiphospholipid antibody syndrome, 448
- protein S deficiency in, 92
- systemic lupus erythematosus and, 87-118
 - antimalarial agents in, 254
 - fetal assessment in, 100-103
 - fetal loss in, 87-93
 - flares in, 96-98
 - in adolescents, 123
 - maternal assessment in, 100
 - maternal outcome in, 96-100
 - preeclampsia vs. lupus nephropathy in, 99-100
 - pregnancy management in, 108-109
 - preterm delivery in, 93-96
 - renal disease in, 98-99
 - treatment of, 103-107
- Pressure algometry, in fibromyalgia, 494-495
- Preterm delivery, in SLE, 93-96
- Primary idiopathic myositis. *See* under *Myositis*.
- Prions, in inclusion body myositis, 963
- Procainamide, in drug-induced lupus, 63
 - antibodies to, 68
 - clinical presentation of, 64-65
 - DNA interactions with, 73
 - genetic factors in, 72-73
 - immunoregulatory abnormalities in, 74
 - laboratory findings in, 66-68
 - in drug-induced myopathy, 1025
- Procollagen peptide, as biochemical marker, for bone formation, 594-595
- Progesterone, in osteoporosis, 708-711
- Progestins, in osteoporosis, 708-711
 - with estrogen therapy, 704
- Proliferating cell nuclear antigen, antibodies to, in SLE, 22-23
- Propylthiouracil, myopathy from, 1027
- Prostaglandins, actions of, in glucocorticoid therapy, 634
 - in osteoporosis, 738-740
 - inhibition of, in lupus nephritis, 237
- Protein, in synovial fluid, 509
- Protein S, deficiency of, in pregnancy, 92
- Protons, in bone resorption, 578
- Proto-oncogenes, in bone resorption, 578
- Pseudolymphoma, in SLE, 184
- Pseudoseptic arthritis, diagnostic arthroscopy in, 331-332
- Pseudotumor cerebri, in SLE, 135
- Psoriatic arthritis, HLA typing in, 372
- osteoporosis in, 573
- Psychosis, from antimalarials, 256-257
- in SLE, 132
- Pulmonary disorders, in drug-induced lupus, 64
 - in eosinophilia myalgia syndrome, 978-979
 - in myositis, juvenile, 928
 - treatment of, 912-913
 - in SLE, 159-193
 - acute lupus pneumonitis, 165-167
 - amyloidosis, 184
 - bronchiolitis obliterans and bronchiolitis obliterans organizing pneumonia, 175-177
 - cavitating nodules, 184
 - chronic interstitial lung disease, 167-171
 - embolism, 182
 - fibrosis, 167-171

- from diaphragmatic dysfunction, 177-178
- hemorrhage, 171-175
 - in pediatric patients, 122
- infectious, 182, 184
- lymphadenopathy, 184
- lymphoid interstitial pneumonitis, 184
- pleural effusion, 162-164
- pulmonary function testing in, 160-162
- vascular disease, 178-181
- Pulmonary embolism, in SLE, 182
- Pulmonary function testing, in
 - inflammatory myopathy, 830
- Pulmonary hypertension, in SLE, 178-181
- Pyarthrosis, diagnostic arthroscopy in, 331-332
- Pyridinoline/deoxypyridinoline, as
 - biochemical marker, for bone resorption, 599-600
- Quantitative computed tomography, in
 - bone density measurement, 658-661, 789
- Quantitative ultrasound, in bone density measurement, 662-663
- Quinacrine, in dermatomyositis, 912
 - in SLE, 253-254
 - adverse reactions to, 255-256, 258
 - chemical structure of, 245
 - in pregnancy, 254
 - mechanisms of action of, 247-248
 - pharmacology of, 244
- Quinidine, in drug-induced lupus, 68-69
- Quinolinic acid, eosinophilia myalgia syndrome from, 982-983
- Quinolones, myopathy from, 1026
- Racial factors, in osteoporosis, 542-543
- Radiation therapy, in SLE, 286
 - total body, in myositis, 909
- Radiographic absorptiometry, in bone density measurement, 652-653
- Radiography, in glucocorticoid therapy, 638
- Raloxifene, in osteoporosis, 705-706
- Rash, in dermatomyositis, treatment of, 912
 - in drug-induced lupus, 64
 - in juvenile myositis, 920-922, 924-925, 933-934
 - in Lyme disease, 362-363
- Raynaud's phenomenon, in anti-synthetase syndrome, 859
 - in myositis, management of, 911-912
 - in SLE, 206
- Sm/U₁RNP antibodies in, 33
- Reflexes, deep tendon, absence of, in spinal stenosis, 476
- Regional acceleratory phenomenon, bone remodeling in, 613
- Reiter's syndrome, HLA typing in, 372-373, 375
- Renal osteodystrophy, bone histomorphometry in, 621-624
- Respiratory disorders. *See Pulmonary disorders.*
- Respiratory system, methotrexate effects on, 521-524
 - vasculitis effects on, 421-422, 427-428
- Reticuloendothelial system, defects in, in lupus nephritis, 231
- Retinal toxicity, in antimalarial therapy, 257-258
- Retrovirus infections. *See also Human immunodeficiency virus infection.*
 - myositis in, 1002-1004
- Rhabdomyolysis, in hypophosphatemia, 1024
- Rheumatoid arthritis, HLA typing in, 376-379
 - juvenile, HLA typing in, 375, 379-380
 - magnetic resonance imaging in, 346-347, 358
 - methotrexate therapy in. *See Methotrexate.*
 - osteoporosis in, 566-572, 630
 - calcitonin therapy for, 781
 - fracture risk in, 571-572
 - from drug therapy, 568, 570-571
 - generalized, 567-571
 - hormone levels in, 632
 - periarticular, 566-567
 - D-penicillamine in, drug-induced lupus from, 69-70
 - predictors in, 309-319
 - acute phase reactants, 313-314
 - age, 311
 - confounding variables in, 314-315
 - erosions, 314
 - for functional outcome, 315
 - for mortality, 315-317
 - gender, 311
 - genetic susceptibility, 309-311
 - number of joints affected, 312
 - rheumatoid factor, 313
 - subcutaneous nodules, 312-313
 - type of onset, 311-312
- Rheumatoid factor, in myositis, 854-855
- rheumatoid arthritis prognosis and, 313
- Rheumatoid nodules, in SLE, 208-209
- Rheumatoid systemic vasculitis, diagnosis of, 416
- Ribonuclear protein, antibodies to, in myositis, 861, 867-869

- Ribosome P, antibodies to, in neuropsychiatric lupus, 141, 143
- Rimmed vacuoles, in inclusion body myositis, 958-959
- Risedronate, in osteoporosis, chemical structure of, 717
prophylactic, 727
- RNA, transfer, in anti-synthetase antibodies, 862
- RNA polymerase transcription complexes, antibodies to, in scleroderma, 11-13
in SLE, 9-14
- RNP (ribonuclear protein), antibodies to, in myositis, 861, 867-869
in SLE, 29-43
- Ro(SSA) antigen, antibodies to, in cutaneous lupus erythematosus, 36-39
in myositis, 861
in neonatal lupus, 37-38, 124-125
in Sjögren's syndrome, 38-39
in SLE, bullous disease and, 201
in Sjögren's syndrome, 404-405
structure of, 34-36
- Ruffled border, bone resorption in, 578-579
- Russell viper venom time, in lupus anticoagulant detection, 456
- Sacroiliitis, magnetic resonance imaging in, 348
- Salivary glands, biopsy of, in Sjögren's syndrome, 394-395
- Sarcoidosis, diagnosis of, 423
magnetic resonance imaging in, 356
- Scleroderma, anti-RNA polymerase transcription complex antibodies in, 11-13
vs. eosinophilia myalgia syndrome, 975
- Sclerosis, lupoid, 135
- Seizures, in SLE, 134
- Senear-Usher syndrome, 202
- Septic arthritis, diagnostic arthroscopy in, 331-332
synovial fluid analysis in, 503-504
culture of, 508-509
- Serology, in neuropsychiatric lupus, 141, 143
- Sex hormones, metabolism of, in lupus nephritis, 233-234
- Sialadenitis, focal, in Sjögren's syndrome, 394
- Signal recognition particles, antibodies to, in myositis, 816-817, 860, 866
- Simvastatin, myopathy from, 1023
- Single photon absorptiometry, in bone density measurement, 653, 789
- Single-photon-emission tomography, in neuropsychiatric lupus, 146-147
- Sjögren's syndrome, antibodies in, 404-405
antimalarial drugs in, 252
clinical features of, 417
diagnosis of, 420, 422
diagnostic criteria for, 391-407
Copenhagen, 398-399
European Epidemiology Center Study Group, 399-400
Greek, 401
historical background of, 392-393
Japanese, 400-401
pitfalls in, 403-405
San Diego, 395-398
San Francisco, 394-395
epidemiology of, 401-402
HLA typing in, 381
La(SSB) antibodies in, 38-39
magnetic resonance imaging in, 348
primary vs. secondary, 402-403
Ro(SSA) antibodies in, 38-39
- Skeleton, fragility of, osteoporosis and, 535-536
intermediary organization of, 610-613
- Skin, antiphospholipid antibody syndrome effects on, 448-449
drug-induced lupus manifestations in, 64
eosinophilia myalgia syndrome manifestations in, 974-976
Lyme disease manifestations in, 362-363
neonatal lupus erythematosus manifestations in, 200
- SLE manifestations in, 195-212
alopecia, 203
bullous lesions, 200-202
cutaneous lupus erythematosus, 196-198
discoid lesions, 195-196
livedo reticularis, 205-206
lupus band test in, 209
malar dermatitis, 199-200
mucinosi, 208
panniculitis, 202-203
photosensitivity, 206-207
Raynaud's phenomenon, 206
rheumatoid nodules, 208-209
subacute cutaneous lupus erythematosus, 36-39, 198-199
urticaria-like vasculitis, 204-205
vasculitis, 203-204
ulcers of, in antiphospholipid antibody syndrome, 52
vasculitis of, 411-416
- SLE. See *Systemic lupus erythematosus*.
- Smoking, osteoporosis risk and, 546
- Sm/U/RNP, antibodies to, clinical relevance of, 31-33
detection of, 30-31

- in mixed connective tissue disease, 32-33
- in Raynaud's phenomenon, 33
- in SLE, 29-34
 - racial differences in, 33-34
 - components of, clinical significance of, 34
 - structure of, 29-30
- Sneddon-Wilkinson disease, 52
- Socioeconomic factors, in rheumatoid arthritis prognosis, 314-315
- Sodium restriction, in osteoporosis, 640
- Spinal cord, disorders of, in SLE, 133-134
- Spinal stenosis, lumbar, diagnosis of, 471-483
- Spleen, dysfunction of, in SLE, 120-121
- Spondyloarthropathy, HLA typing in, 372-376
 - osteoporosis in, 572-573
 - seronegative, magnetic resonance imaging in, 347-348, 352-353, 357
- SRP (signal recognition particle) antibodies, in myositis, 860, 866
- SSA antigen. See *Ro(SSA) antigen*.
- SSB antigen. See *La(SSB) antigen*.
- Stenosis, spinal, diagnosis of, 471-483
- Straight leg raising test, in spinal stenosis, 475-476
- Strength testing, in inflammatory myopathy, 830-835, 840
- Stress tests, fetal, in SLE, 102
- String test, on synovial fluid, 510
- Stroke, in antiphospholipid antibody syndrome, 48, 54-55
 - in SLE, 133
- Subcutaneous nodules, rheumatoid arthritis prognosis and, 312-313
- Sulfadiazine, lupus from, 61
- Sulfasalazine, drug-induced lupus from, 71
- Sulfonamides, myopathy from, 1026
- Suxamethonium, myopathy from, 1027
- Sweet's syndrome, in drug-induced lupus, 64
- Synovial fluid, analysis of, 503-512
 - cell count in, 506-507
 - chemistry studies in, 509-510
 - culture in, 508-509
 - differential count in, 507-508
 - Gram stain of, 508-509
 - indications for, 503-505
 - methods for, 505-506
 - polarizing microscopy in, 510
 - results interpretation in, 511-512
- Synovitis, magnetic resonance imaging in, 349, 353
- Synovium, features of, in rheumatic disease, 328-329
- Synthetase, antibodies to, in myositis, 816-817, 858-860, 862-866
- Syphilis, antiphospholipid antibody syndrome from, 47
- Syphilis test, false-positive, antiphospholipid antibodies in, 443-444
- Systemic lupus erythematosus, ANA-negative, 36-37
 - antibodies in, 1-28
 - to chromatin, 23-24
 - to DNA, 2-5, 8
 - to DNA replication/repair complexes, 21-23
 - to histones, 5, 7-8
 - to Ku antigen, 14-21
 - to nucleosomes, 5, 7-8
 - to proliferating cell nuclear antigen, 22-23
 - to ribonuclear proteins, 29-43
 - to RNA polymerase transcription complexes, 9-14
 - to Sm/U,RNP, 29-34
 - to transcription complexes, 9-14
 - antiphospholipid antibodies in, 46, 451-453
 - cardiovascular manifestations of, in pediatric patients, 122-123
 - clinical manifestations of, in pediatric patients, 119-123
 - cutaneous manifestations of. See *Skin, SLE manifestations in*.
 - death in, in pediatric patients, 119
 - diagnosis of, 420, 423-424, 426
 - epidemiology of, in pediatric patients, 119-120
 - flares of, in pregnancy, 96-98
 - growth abnormalities in, in pediatric patients, 123
 - HLA typing in, 381
 - hormone levels in, osteoporosis and, 632
 - in pediatric patients, 119-127. See also *Neonatal lupus erythematosus*.
 - in neonates, 37-38, 134-135, 200
 - treatment of, 276
 - infections with, in pediatric patients, 120-121
 - laboratory findings in, in pediatric patients, 123
 - musculoskeletal manifestations of, in pediatric patients, 123
 - nail changes in, 208
 - neuropsychiatric. See *Neuropsychiatric lupus erythematosus*.
 - oral mucosa ulceration in, 207-208
 - pregnancy and. See under *Pregnancy*.
 - pulmonary disorders in. See under *Pulmonary disorders*.
 - thrombosis in, 453-454
 - treatment of. See also *Immunosuppressive therapy; specific drug*.
 - antimalarial agents in, 243-264

- Systemic lupus erythematosus (*Continued*)
 iatrogenic neuropsychiatric symptoms
 from, 136-137
 in pediatric patients, 123-124
 in pregnancy, 103-107
 plasmapheresis in, with cyclophosphamide, 286
 total lymphoid irradiation in, 286
 with pemphigus, 202
- T lymphocytes, cytotoxic, in inclusion body myositis, 962
 in eosinophilia myalgia syndrome, 983-984
 in inflammatory myopathy, 883-889
 myotoxic action of, 888-889
 subsets of, 886-887
 in juvenile myositis, 930
 Takayasu's arteritis, case study of, 436-438
 diagnosis of, 423, 430-432
 HLA typing in, 382
 treatment of, 412
 Tamoxifen, in osteoporosis, 705-706
 Tartrate-resistant acid phosphatase, as biochemical marker, for bone resorption, 596
 Telopeptides, collagen, as biochemical markers, for bone resorption, 600, 602
 Temporal arteritis. *See Giant cell (temporal) arteritis.*
 Tender points, in fibromyalgia, 492-495
 Teratogenic effects, of methotrexate, 524
 Testosterone, in osteoporosis, 640, 678-680
 levels of, in glucocorticoid therapy, 640
 vs. bone density, 678-680
 Tetracyclines, for bone specimen labeling, 614-615
 Thiazides, in osteoporosis prevention, 548, 639-640, 698-699
 Thrombocytopenia, in antiphospholipid antibody syndrome, 55, 448
 Thrombosis, in antiphospholipid antibody syndrome, 48-50, 54-55, 448-449
 in SLE, antimalarial effects on, 251-252
 in systemic lupus erythematosus, 453-454
 Thymectomy, in myositis, 910
 Tiludronate, in osteoporosis, chemical structure of, 717
 pharmacodynamics of, 719
 prophylactic, 726-727
 side effects of, 719-720
 Tooth loss, in osteoporosis, 539
 Total body irradiation, in myositis, 909
 Total lymphoid irradiation, in SLE, 286
 Toxic oil syndrome, 973
 myositis in, 818
 Toxins, myositis from, 817-818
 Toxoplasmosis, myositis in, 1004-1009
 Trabecular bone volume, measurement of, 617
 Trabecular continuity, measurement of, 618
 Transcription complexes, antibodies to, in scleroderma, 11-13
 in SLE, 9-14
 Transfer RNA, in anti-synthetase antibodies, 862
 Transforming growth factor- β , in bone remodeling, 581-582
 glucocorticoid effects on, 635
 in bone resorption, 578
 in eosinophilia myalgia syndrome, 984-985
 Transplantation, myositis after, 818
 Transverse myelitis, in SLE, 133-134
 Trephines, for bone biopsy, 613-614
 Triamcinolone, myopathy from, 1018-1019
 Trichinosis, myositis in, 1010
 Trochanteric bursitis, vs. lumbar spinal stenosis, 479
 Trypanosomiasis, American, myositis in, 1009-1010
 L-Tryptophan, myopathy from, 973, 980-987, 1022
 Tuberculosis, in SLE, 184
 Tumor necrosis factors, in bone resorption, 579, 745
 in inflammatory myopathy, 889, 891-892
- Ulceration, gastrointestinal, in myositis, 914
 in antiphospholipid antibody syndrome, 52
 of oral mucosa, in SLE, 207-208
 Ultrasonography, in fetal assessment, in SLE, 100-102
 quantitative, in bone density measurement, 662-663
 Ultraviolet light, sensitivity to, in SLE, 206-207
 Umbilical artery flow velocity monitoring, in SLE, 102-103
 Urate crystals, in synovial fluid, microscopy of, 510
 U1RNP antigen, antibodies to, in myositis, 861, 867-869
 U2RNP antigen, antibodies to, in myositis, 861, 869
 U3RNP antigen, antibodies to, in myositis, 870
 Urticaria-like vasculitis, in SLE, 204-205
 Uterine artery flow velocity monitoring, in SLE, 102-103

- Vacuoles, rimmed (lined), in inclusion body myositis, 958-959
- Valvular heart disease, in antiphospholipid antibody syndrome, 52, 55
- Vascular occlusion, in antiphospholipid antibody syndrome, 48-50, 54-56
in SLE, 139-140
- Vasculitis, brain, in SLE, 137-138, 140
cutaneous, in SLE, 203-204
diagnosis of, 409-442
 biopsy in, 427-428
 differential, 410
 initial, 411
 laboratory testing in, 426-427
 of large arteries, 430-434
 of small and medium-sized blood vessels, 416-430
 of small blood vessels, 411-416
established, differential diagnostic considerations in, 434-439
HLA typing in, 381-382
hypersensitivity, 411-416
in juvenile myositis, 928-930
systemic, diagnosis of, 416
treatment of, 412-413
- VDRL test, false-positive, antiphospholipid antibodies in, 443-444
- Venous occlusion syndromes, in antiphospholipid antibody syndrome, 49-50, 55
- Vertebral fractures, in ankylosing spondylitis, 573
in osteoporosis, epidemiology of, 537-540
 calcitonin therapy effects on, 780
 gender differences in, 672
 etidronate therapy for, 720-724
in men, 681
vitamin D supplementation and, 697-698
- Vibratory sensation, loss of, in spinal stenosis, 476
- Vincristine, myopathy from, 1027
- Viral infections, myositis in, adenovirus, 962
 coxsackievirus, 997-1001
 echovirus, 933, 1001-1002
 encephalomyocarditis, 1002
 enterovirus, 997
 hepatitis B, 1004
 human immunodeficiency virus, 1002-1003
 human T-cell lymphotropic virus, 1003-1004
 inclusion body, 962-963
 juvenile, 924, 933
 mumps, 962-963, 1004
 paramyxovirus, 962-963
 retrovirus, 1002-1004
 myositis-associated antibodies in, 871-873
- Vitamin D and metabolites, 759-775
 calcium absorption and, 762-763
 deficiency of, in glucocorticoid therapy, 632-633
 osteomalacia and, 621-624
 osteoporosis and, 547-548, 762-766
 in bone remodeling, 760-762
 levels of, vs. age, 763, 765-766
 measurement of, in glucocorticoid therapy, 637
 supplementation with, in osteoporosis, 639, 697-698, 766-769
 in established disease, 736
 tissue resistance to, 765
- Von Willebrand factor-associated antigen, in myositis, 931
- Wall thickness, measurement of, 618
- Warfarin, in antiphospholipid antibody syndrome, 54-55
in myositis, 912
interference by, in lupus anticoagulant detection, 457
- Weakness, in corticosteroid therapy, 1019
in inclusion body myositis, 956-957
in juvenile myositis, 920-921, 927, 935
in spinal stenosis, 475
- Wegener's granulomatosis, case studies of, 434-436, 438-439
clinical features of, 417
diagnosis of, 415, 418-423, 425, 427-428
HLA typing in, 382
treatment of, 413
- Weight, loss of, in myositis, 911
vs. osteoporosis risk, 545-546
- White blood cell count, in synovial fluid, 506-508
- World Health Organization, lupus nephritis classification of, 213-221
- Wrist fractures, in osteoporosis, epidemiology of, 543
- Zidovudine, myopathy from, 1021-1022